Publikationen in Zusammenarbeit mit Forschern von Instituto de Biomedicina y Biotecnología de Cantabria (11)

2019

  1. Dopaminergic control of ADAMTS2 expression through cAMP/CREB and ERK: molecular effects of antipsychotics

    Translational Psychiatry, Vol. 9, Núm. 1

  2. Opioid Activity in the Locus Coeruleus Is Modulated by Chronic Neuropathic Pain

    Molecular Neurobiology, Vol. 56, Núm. 6, pp. 4135-4150

  3. Regulation of Human Hsc70 ATPase and Chaperone Activities by Apg2: Role of the Acidic Subdomain

    Journal of Molecular Biology, Vol. 431, Núm. 2, pp. 444-461

2018

  1. Selective up-regulation of cannabinoid CB1 receptor coupling to Go-proteins in suicide victims with mood disorders

    Biochemical Pharmacology, Vol. 157, pp. 258-265

  2. The endocannabinoid system in mental disorders: Evidence from human brain studies

    Biochemical Pharmacology, Vol. 157, pp. 97-107

2017

  1. Antipsychotic-induced Hdac2 transcription via NF-ΰ B leads to synaptic and cognitive side effects

    Nature Neuroscience, Vol. 20, Núm. 9, pp. 1247-1259

2016

  1. Allosteric signaling through an mGlu2 and 5-HT2A heteromeric receptor complex and its potential contribution to schizophrenia

    Science Signaling, Vol. 9, Núm. 410

2014

  1. FADD adaptor and PEA-15/ERK1/2 partners in major depression and schizophrenia postmortem brains: Basal contents and effects of psychotropic treatments

    Neuroscience, Vol. 277, pp. 541-551

2010

  1. Long-term fluoxetine treatment modulates cannabinoid type 1 receptor-mediated inhibition of adenylyl cyclase in the rat prefrontal cortex through 5-hydroxytryptamine1A receptor-dependent mechanisms

    Molecular Pharmacology, Vol. 77, Núm. 3, pp. 424-434

2008

  1. Gene expression patterns in brain cortex of three different animal models of depression

    Genes, Brain and Behavior, Vol. 7, Núm. 6, pp. 649-658

2007

  1. CB1 knockout mice display impaired functionality of 5-HT 1A and 5-HT2A/C receptors

    Journal of Neurochemistry, Vol. 103, Núm. 5, pp. 2111-2120